STOCK TITAN

Evotec SE American Depositary Shares - EVO STOCK NEWS

Welcome to our dedicated page for Evotec SE American Depositary Shares news (Ticker: EVO), a resource for investors and traders seeking the latest updates and insights on Evotec SE American Depositary Shares stock.

Evotec SE, headquartered in Hamburg, Germany, is a leading global drug discovery and development company. Specializing in providing comprehensive solutions to pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations, Evotec is renowned for its extensive capabilities in therapeutic areas such as central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health.

Evotec’s core business is divided into two main segments: Shared R&D and Just-Evotec Biologics. The Shared R&D segment, making up approximately 80% of the company's sales, offers drug discovery and manufacturing services on a fee-for-service basis. It also engages in integrated drug discovery collaborations leveraging proprietary, internally-developed assets. Just-Evotec Biologics, accounting for about 20% of sales, provides contract development and manufacturing (CDMO) services for biologics.

With a workforce of over 5,000 employees, Evotec operates 18 production sites mainly across Europe and the United States. In recent years, the company has made significant strides in forming strategic alliances and collaborations, such as the recent partnership with Claris Ventures and Variant Bio, aimed at accelerating the development of innovative therapeutics.

Evotec’s multimodal platform combines cutting-edge technologies, data, and scientific expertise to drive the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. The company’s integrated R&D network includes partnerships with all Top 20 Pharma companies and over 800 biotech companies, academic institutions, and other healthcare stakeholders. This robust network facilitates the co-creation of a world-leading pipeline of over 200 proprietary and co-owned R&D projects, ranging from early discovery to clinical development.

Recent achievements by Evotec include the successful Clinical Trial Application (CTA) for IAMA Therapeutics’ lead program IAMA-6 and the strategic collaboration with Janssen for immune-based therapies. Additionally, Evotec has expanded its relationship with Bristol Myers Squibb in neurodegeneration and targeted protein degradation.

Financially, Evotec has demonstrated resilience despite macroeconomic challenges and a substantial cyber-attack in 2023. The company reported a 4% increase in revenues, reaching €781.4 million in 2023, driven by new collaborations and the strong performance of Just-Evotec Biologics.

As of 2024, Evotec continues to focus on sustainable and profitable growth, optimizing its operations to meet evolving market demands. The company is committed to advancing its mission of discovering and developing effective therapeutics that address unmet medical needs globally.

Rhea-AI Summary

Evotec SE will announce its 2021 financial results on April 12, 2022. A conference call to discuss the results and provide performance updates will take place at 02:00 PM CEST (08:00 AM EDT). Participants can join through a dedicated phone line or an audio webcast, with the on-demand version available post-event on their website. Evotec's unique business model focuses on discovering and developing therapeutics across various therapeutic areas, supported by partnerships with major pharmaceutical and biotechnology firms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.26%
Tags
-
Rhea-AI Summary

Evotec has received a milestone payment of €3 million from Bayer AG due to the advancement of BAY 2395840 into Phase II clinical trials for diabetic neuropathic pain (DNP). This investigational oral antagonist targets the bradykinin receptor B1, known to influence pain perception. The Phase II trial aims to assess its safety and efficacy compared to a placebo and is expected to conclude by the end of 2022. Dr. Cord Dohrmann expressed optimism about BAY 2395840's potential to offer a new therapeutic option for DNP patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
-
Rhea-AI Summary

Evotec has launched E.MPD, a global molecular patient database, aimed at enhancing drug development through AI and machine learning technologies. The initiative is part of Evotec's strategy to increase the probability of success (PoS) in therapeutics research. The company confirmed its goals for Action Plan 2025 and announced the appointment of Dr. Matthias Evers as Chief Business Officer to lead business development. Evotec is focused on establishing itself as a leader in precision medicine, leveraging partnerships and innovative technologies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.48%
Tags
none
Rhea-AI Summary

Evotec announced a collaboration with the University of Bristol to enhance its molecular patient database focusing on nephrotic syndrome. This partnership grants Evotec access to an international cohort's longitudinal clinical data and biospecimens from hundreds of patients across Asia, India, and Africa. Evotec plans to utilize its multi-omics platforms, EVO panOmics and EVO panHunter, to identify disease mechanisms and diagnostic markers, aiming for new targeted therapies. This collaboration could significantly impact treatment options for nephrotic syndrome patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
none
-
Rhea-AI Summary

Evotec SE (NASDAQ: EVO) has made an equity investment in IMIDomics, Inc., a biotechnology firm focusing on treatments for immune-mediated inflammatory diseases (IMIDs). The investment will allow Evotec to participate in IMIDomics' board of directors while supporting the advancement of its Precision Discovery™ Engine. This initiative integrates patient biological data and clinical expertise to identify effective treatments for over 17,000 IMID patients. The collaboration aims to develop targeted medicines addressing unmet medical needs in the field.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.87%
Tags
none
-
Rhea-AI Summary

Evotec SE announced that Bayer has discontinued the development of eliapixant (BAY1817080), an investigational P2X3 receptor antagonist. Bayer determined that the risks outweigh the benefits after reviewing the available data. As a result, Evotec regains rights to all P2X3 assets and will evaluate the data and options moving forward. The company states that this change does not affect its strategic goals outlined in the Action Plan 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.07%
Tags
Rhea-AI Summary

Evotec SE announced a partnership with Boehringer Ingelheim focusing on induced pluripotent stem cell (iPSC)-based disease modeling for ophthalmologic disorders. This collaboration aims to identify and validate therapeutic targets through phenotypic screening and Evotec's PanOmics platform, addressing a significant unmet need in vision-related diseases. The partnership includes undisclosed upfront payments and ongoing royalties for successful therapeutic development. Dr. Cord Dohrmann highlighted the potential of their unique methodologies to deliver effective drugs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
partnership
-
Rhea-AI Summary

Evotec SE has announced a drug discovery collaboration with Eli Lilly focusing on metabolic diseases, particularly kidney diseases and diabetes. This partnership will leverage Evotec's extensive kidney disease patient database and metabolic expertise to identify novel therapeutic targets. Over three years, Lilly can select up to five programs, potentially generating up to $1 billion in total value for Evotec, including milestone payments and royalties. This collaboration underscores Evotec's commitment to innovative drug development in underserved therapeutic areas.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
none
-
Rhea-AI Summary

Evotec has expanded its collaboration with Bristol Myers Squibb to target neurodegenerative diseases like Alzheimer's through a novel protein degradation strategy. This expansion includes a payment of US$ 15 million from Bristol Myers Squibb. The partnership, initiated in December 2016, aims to discover disease-modifying treatments using Evotec's advanced patient-derived disease models. Dr. Cord Dohrmann highlighted the collaboration's productivity and commitment to innovative drug targeting mechanisms, addressing the significant unmet medical need in treating neurodegenerative conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.55%
Tags
none
Rhea-AI Summary

Evotec announced it has received a €7.5 million grant from the German Federal Ministry of Education and Research to develop EVT075, a potential first-in-class immunomodulatory therapy targeting COVID-19. This funding aims to facilitate clinical studies assessing the safety and efficacy of the compound, which has shown promising results against SARS-CoV-2 in pre-clinical studies. The therapy aims to amplify the immune response and reduce hospitalizations related to COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
covid-19

FAQ

What is the current stock price of Evotec SE American Depositary Shares (EVO)?

The current stock price of Evotec SE American Depositary Shares (EVO) is $5.3 as of November 20, 2024.

What is the market cap of Evotec SE American Depositary Shares (EVO)?

The market cap of Evotec SE American Depositary Shares (EVO) is approximately 1.8B.

What is Evotec SE?

Evotec SE is a global drug discovery and development company headquartered in Hamburg, Germany. It provides comprehensive solutions in drug discovery and manufacturing to pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations.

What are Evotec's main business segments?

Evotec's business is divided into Shared R&D, which offers drug discovery and manufacturing services, and Just-Evotec Biologics, which provides CDMO services for biologics.

Who are Evotec's partners?

Evotec collaborates with all Top 20 Pharma companies, over 800 biotech companies, academic institutions, and other healthcare stakeholders.

What recent collaborations has Evotec entered into?

Recent collaborations include partnerships with Claris Ventures to accelerate programs into the clinic and with Variant Bio to develop treatments for fibrotic diseases.

How many employees does Evotec have?

Evotec employs over 5,000 people across 18 production sites in Europe and the United States.

What are Evotec's key therapeutic areas?

Evotec focuses on central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health.

What financial performance did Evotec report in 2023?

Evotec reported a 4% increase in revenues, reaching €781.4 million in 2023, despite challenging economic conditions and a cyber-attack.

What are the future goals of Evotec?

Evotec aims to focus on sustainable and profitable growth, optimizing its operations and continuing to advance its mission of developing effective therapeutics.

What is Just-Evotec Biologics?

Just-Evotec Biologics is a segment of Evotec that offers contract development and manufacturing services for biologics.

What makes Evotec's platform unique?

Evotec’s multimodal platform combines innovative technologies, data, and scientific expertise to drive the discovery, development, and production of first-in-class and best-in-class pharmaceutical products.

Evotec SE American Depositary Shares

Nasdaq:EVO

EVO Rankings

EVO Stock Data

1.85B
354.61M
2.34%
0.06%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Hamburg